Protocol Ledger

NCT05936151 · Phase II · COMPLETED

A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Interventional Phase II clinical trial protocol NCT05936151 sponsored by Eli Lilly and Company in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-07-20 Enrollment: 146 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05936151
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)146 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05936151
Protocol FieldVerified Registry Value
NCT IdentifierNCT05936151
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment146 participants (ACTUAL)
Registered Start Date2023-07-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05936151
Hospital Research SiteLocationSite Profile
Catalina Research Institute, LLCMontclair, CAOpen Hospital Dossier ->
University of Colorado Anschutz Medical CampusAurora, COOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI